Prescient Therapeutics Ltd has released a press release.
First Patient Dosed on Phase 1b/2 AML Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
- September 2016 Appendix 4C - Quarterly
- First patient at Moffitt dosed in Phase 1b/2 breast trial
- Appendix 4E and 2016 Annual Report
- USPTO Grants Allowances for Two PTX-200 Patents
Later from Prescient Therapeutics
- December 2016 Appendix 4C - Quarterly
- First Cohort Successfully Completed in Phase 1b/2 AML Trial
- Three Additional US Patents Granted
- Successful Completion of Phase 1b Breast Cancer Trial
- March 2017 Appendix 4C - Quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics